Corvus Pharmaceuticals
CRVS
58 hedge funds and large institutions have $99.5M invested in Corvus Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 6 closing their positions.
8% more capital invested
Capital invested by funds: $92.2M → $99.5M (+$7.37M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.39% less ownership
Funds ownership: 85.83% → 84.44% (-1.4%)
5% less funds holding
Funds holding: 61 → 58 (-3)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$957K |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$924K |
| 3 |
Renaissance Technologies
New York
|
+$504K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$359K |
| 5 |
Morgan Stanley
New York
|
+$97.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.08M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$826K |
| 4 |
CI
Cowen Inc
New York
|
-$317K |
| 5 |
JP Morgan Chase
New York
|
-$262K |
CRVS Hedge Fund Activity: Q1 2019 in Review
58 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2019, worth a combined $99.5M — up 8% from $92.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CRVS and 3 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 19 added.
The largest buyer was Vanguard Group, adding an estimated $957K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $1.08M sold.
- 58 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2019, down from 61 in Q4 2018.
- Funds reported $99.5M of Corvus Pharmaceuticals stock for Q1 2019, up 8% quarter-over-quarter.
- 3 funds opened new Corvus Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of -3 holders.
- The largest Corvus Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $957K added.
- The largest Corvus Pharmaceuticals seller in Q1 2019 was EcoR1 Capital, an estimated $1.08M sold.
Based on aggregated 13F filings for Q1 2019.